Background: The assessment of cardiac wall motion abnormalities plays an important role in the evaluation of many cardiovascular diseases and the prediction of functional recovery. Most of the methods dedicated to identifying the location of wall motion abnormalities have been restricted to study hypokinesia while an accurate way to assess dyskinesia is still needed in Cardiac Magnetic Resonance Imaging (CMRI).
Objective: The aim of this study is to propose a phase image based on the analytic signal able to assess the extent of the myocardial dyskinetic segments in Cardiac Magnetic Resonance Imaging (CMRI).
Materials: 22 subjects were retrospectively enrolled in this study (age 46 ± 11): 15 presenting an aneurysm and 7 control subjects with normal wall motion. For each patient, three standard views (short axis view, 2 chamber and 4 chamber views) were acquired using 3 Tesla Siemens Avanto MRI scanner and a segmented True FISP sequence. All the cine MRI images were analyzed by two experimented observers who were blinded to the diagnostic results.
Results: The outcomes of this study show that using the proposed phase image in MRI clinical routine can increase the accuracy of the detection of myocardial dyskinetic segments from 77.23 % to 86.38 %, the sensitivity from 67.48 % to 78.86 % as well the specificity from 80.92 % to 89.23 % compared to the standard method based on cine MRI interpretation.
Conclusion: The phase image is a promising tool in CMRI for the assessment of dyskinetic segments and the degree of myocardial asynchronism.
Keywords: Phase image, assessment, dyskinesia, wall motion abnormalities, CMRI, myocardium.
A Genetic Dissection of Antipsychotic Induced Movement Disorders
Current Medicinal Chemistry Receptor-Binding and Pharmacokinetic Properties of Dopaminergic Agonists
Current Topics in Medicinal Chemistry The Evolution of Pharmacological Treatment for Parkinsons Disease
Recent Patents on CNS Drug Discovery (Discontinued) Gene-Gene Interactions in a Context of Individual Variability in Antipsychotic Drug Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics) L-Dopa Prodrugs: An Overview of Trends for Improving Parkinsons Disease Treatment
Current Pharmaceutical Design Challenge and Therapeutic Studies Using Alpha-Methyl-para-Tyrosine (AMPT) in Neuropsychiatric Disorders: A Review
Central Nervous System Agents in Medicinal Chemistry Poor Prognostic Outcome in Cerebral Venous Sinus Thrombosis Associated with Dyskinesia and Elevated Platelet Volume
Current Neurovascular Research The Use of Antiparkinsonian Agents in the Management of Drug-Induced Extrapyramidal Symptoms
Current Pharmaceutical Design Phenytoin Induced Chorea: A Rare Adverse Effect of the Drug
Current Drug Safety The Surgical Management of Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Prevalence, Severity and Characteristics of Tardive Dyskinesia Among Schizophrenia Patients in an Israeli Psychiatric Center
Current Psychopharmacology Etiopathogenesis and Treatment of Parkinsons Disease
Current Topics in Medicinal Chemistry Targeting Nicotinic Receptors for Parkinson's Disease Therapy
CNS & Neurological Disorders - Drug Targets Recent Developments in Studies of l-Stepholidine and its Analogs: Chemistry, Pharmacology and Clinical Implications
Current Medicinal Chemistry Antidepressant Related Movement Disorders in the Elderly
Current Psychiatry Reviews The Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): A New Rodent Model to Test Palliative and Neuroprotective Agents for Parkinsons disease
Current Pharmaceutical Design Therapeutic Strategies in Parkinsons Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Under Re-organization) Pharmacogenomic-Guided Rational Therapeutic Drug Monitoring: Conceptual Framework and Application Platforms for Atypical Antipsychotics
Current Medicinal Chemistry New Trends in the Treatment of Schizophrenia
CNS & Neurological Disorders - Drug Targets Dopamine: Agonists and Neurodegenerative Disorders
Current Drug Targets